Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Melvin Lafeber

Showing results (1-10 of 40) with videos related to

Pageof 4
Sort By:
Nederlands Tijdschrift Voor Geneeskunde|December 21, 2018
[The polypill for cardiovascular disease: why is it used so infrequently?]Michiel L Bots, Melvin Lafeber
The New England Journal of Medicine|February 3, 2018
Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial FibrillationTanja Dekkers, Melvin Lafeber, Cornelis Kramers
Nederlands Tijdschrift Voor Geneeskunde|April 6, 2023
[When will we treat patients with a polypill shortly after myocardial infarction?]Melvin Lafeber, Laura Peeters, Jori Versmissen
Nederlands Tijdschrift Voor Geneeskunde|March 15, 2023
[How to cope with the nocebo effects of statins?]Melvin Lafeber, Andrea W M Evers, Frederikus A Klok
European Journal of Preventive Cardiology|October 25, 2011
The cardiovascular polypill in high-risk patientsMelvin Lafeber, Wilko Spiering, Kavita Singh, et al.
Nederlands Tijdschrift Voor Geneeskunde|April 24, 2020
[Medicines: what has the last decade given us and what can we expect in the coming 10 years?]Melvin Lafeber, Rafke Schoffelen, Rebecca J Verheggen, et al.
International Journal of Cardiology|February 17, 2022
Adequacy of blood pressure control in high-risk hypertensive patients: The DEGREE studyVictor J M Zeijen, Melvin Lafeber, Jorie Versmissen, et al.
Nederlands Tijdschrift Voor Geneeskunde|November 10, 2011
[Cardiovascular polypill in high risk patients]Melvin Lafeber, Wilko Spiering, Michiel L Bots, et al.
European Journal of Preventive Cardiology|January 9, 2016
Estimated cardiovascular relative risk reduction from fixed-dose combination pill (polypill) treatment in a wide range of patients with a moderate risk of cardiovascular diseaseMelvin Lafeber, Ruth Webster, Frank Lj Visseren, et al.
European Journal of Preventive Cardiology|June 1, 2012
The combined use of aspirin, a statin, and blood pressure-lowering agents (polypill components) in clinical practice in patients with vascular diseases or type 2 diabetes mellitusMelvin Lafeber, Diederick E Grobbee, Wilko Spiering, et al.
Pageof 4

Showing results (1-10 of 40) with videos related to

Sort By:
Pageof 4
Nederlands Tijdschrift Voor Geneeskunde|December 21, 2018
[The polypill for cardiovascular disease: why is it used so infrequently?]Michiel L Bots, Melvin Lafeber
The New England Journal of Medicine|February 3, 2018
Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial FibrillationTanja Dekkers, Melvin Lafeber, Cornelis Kramers
Nederlands Tijdschrift Voor Geneeskunde|April 6, 2023
[When will we treat patients with a polypill shortly after myocardial infarction?]Melvin Lafeber, Laura Peeters, Jori Versmissen
Nederlands Tijdschrift Voor Geneeskunde|March 15, 2023
[How to cope with the nocebo effects of statins?]Melvin Lafeber, Andrea W M Evers, Frederikus A Klok
European Journal of Preventive Cardiology|October 25, 2011
The cardiovascular polypill in high-risk patientsMelvin Lafeber, Wilko Spiering, Kavita Singh, et al.
Nederlands Tijdschrift Voor Geneeskunde|April 24, 2020
[Medicines: what has the last decade given us and what can we expect in the coming 10 years?]Melvin Lafeber, Rafke Schoffelen, Rebecca J Verheggen, et al.
International Journal of Cardiology|February 17, 2022
Adequacy of blood pressure control in high-risk hypertensive patients: The DEGREE studyVictor J M Zeijen, Melvin Lafeber, Jorie Versmissen, et al.
Nederlands Tijdschrift Voor Geneeskunde|November 10, 2011
[Cardiovascular polypill in high risk patients]Melvin Lafeber, Wilko Spiering, Michiel L Bots, et al.
European Journal of Preventive Cardiology|January 9, 2016
Estimated cardiovascular relative risk reduction from fixed-dose combination pill (polypill) treatment in a wide range of patients with a moderate risk of cardiovascular diseaseMelvin Lafeber, Ruth Webster, Frank Lj Visseren, et al.
European Journal of Preventive Cardiology|June 1, 2012
The combined use of aspirin, a statin, and blood pressure-lowering agents (polypill components) in clinical practice in patients with vascular diseases or type 2 diabetes mellitusMelvin Lafeber, Diederick E Grobbee, Wilko Spiering, et al.
Pageof 4